Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q3

4483.TEDINET S100SUYD
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥22.3bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥8.5bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥19.5bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥7.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥5.7bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥2.1bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥4.0bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥1.8bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥5.6bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥2.0bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥4.0bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥1.8bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥4.0bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.3bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥1.3bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥103.6bnat 2023-12-31Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥95.1bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥33.6bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥70.0bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥62.9bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥70.0bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥62.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥17.0bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥2.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥9.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥21.8bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥2.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥27.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥62.312023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥20.142023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥44.982022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.282022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥60.442023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.912023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.662022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥18.452022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio67.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.1%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 71
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥102m
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥12m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥102m
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥12m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥515m
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥176m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-10-01 → 2023-12-31¥301m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-12-31¥1.5bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-10-01 → 2023-12-31¥301m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥50m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-12-31¥175m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-10-01 → 2023-12-31¥41m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-12-31¥16.6bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2023-10-01 → 2023-12-31¥6.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-12-31¥16.6bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-10-01 → 2023-12-31¥6.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥51m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥12m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-12-31¥5.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-10-01 → 2023-12-31¥2.5bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-12-31¥4.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2023-10-01 → 2023-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-12-31¥4.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2023-10-01 → 2023-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-12-31¥1.6bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2023-10-01 → 2023-12-31¥556m
—segment totalrevenue2023-04-01 → 2023-12-31¥22.4bn
—segment totalrevenue2023-10-01 → 2023-12-31¥8.5bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥22.3bn
—segment totalrevenue external2023-10-01 → 2023-12-31¥8.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥102m
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥12m
—segment totalsegment profit2023-04-01 → 2023-12-31¥6.7bn
—segment totalsegment profit2023-10-01 → 2023-12-31¥3.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥417m
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥227m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-12-31¥2.8bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-10-01 → 2022-12-31¥944m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-10-01 → 2022-12-31¥901m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥127m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥43m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-12-31¥310m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-10-01 → 2022-12-31¥118m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥62m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥19m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-12-31¥4.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-10-01 → 2022-12-31¥2.0bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-10-01 → 2022-12-31¥492m
—segment totalrevenue2022-04-01 → 2022-12-31¥19.7bn
—segment totalrevenue2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥19.5bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥189m
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥62m
—segment totalsegment profit2022-04-01 → 2022-12-31¥5.7bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 846
ItemContextValueUnit
Total transactions with owners IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember8000000JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-562000000JPY
Total transactions with owners IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember29048000000JPY
Total transactions with owners IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember-15000000JPY
Total transactions with owners IFRSPrior1YTDDuration29032000000JPY
Equity IFRSPrior1QuarterInstant_OtherComponentsOfEquityIFRSMember29000000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember11672000000JPY
Equity IFRSPrior1QuarterInstant_EquityAttributableToOwnersOfParentIFRSMember62877000000JPY
Equity IFRSPrior1QuarterInstant_NonControllingInterestsIFRSMember-19000000JPY
Equity IFRSPrior1QuarterInstant62857000000JPY
Equity IFRSPrior1YearInstant_ShareCapitalIFRSMember23994000000JPY
Equity IFRSPrior1YearInstant_CapitalSurplusIFRSMember27211000000JPY
Equity IFRSPrior1YearInstant_TreasurySharesIFRSMember-2000000JPY
Equity IFRSPrior1YearInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-4000000JPY
Equity IFRSPrior1YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Equity IFRSPrior1YearInstant_ShareAcquisitionRightsIFRSMember32000000JPY
Profit loss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-0JPY
Other comprehensive income IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember3000000JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-0JPY
Comprehensive income IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember3000000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember6000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember1102000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember1102000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember-8000000JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember0JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass